STOCK TITAN

AstraZeneca receives EU approval for Klygefa

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

AstraZeneca PLC announced that the European Commission approved Klygefa (gefurulimab) on November 16, 2026, as an add-on to standard therapy for adults with AChR antibody-positive generalised myasthenia gravis (gMG). It is the first and only dual-binding nanobody C5 inhibitor approved in the EU and is administered once weekly by subcutaneous autoinjector.

In the PREVAIL Phase III trial, Klygefa met its primary endpoint: at week 26, the MG-ADL score treatment difference versus placebo was -1.6 (95% CI: -2.4 to -0.8; p<0.0001). Improvement was observed as early as week one and sustained through week 26. Klygefa was generally well tolerated, with a safety profile consistent with previous trials of C5 inhibitors in gMG.

1 point · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Major pointEU approval on November 16, 2026 covers adults with AChR-positive gMG.

Negative

  • None.

Filing Explained

AstraZeneca also reports that submissions based on PREVAIL remain under review in China and additional countries, while the trial’s open-label extension is ongoing and continues to evaluate safety and efficacy.

EU approval date November 16, 2026 European Commission approval for Klygefa to treat eligible adults with gMG
MG-ADL treatment difference -1.6 points Versus placebo at week 26; 95% CI: -2.4 to -0.8
Primary endpoint p-value <0.0001 PREVAIL Phase III trial, week 26 MG-ADL result
Trial enrollment 260 patients PREVAIL trial participants enrolled from 20 countries
Estimated diagnosed population 82,500 people People with gMG across Germany, France, the UK, Italy and Spain
Estimated AChR-positive population approximately 66,000 people People with gMG in the five listed European countries
dual-binding nanobody technical
"first and only dual-binding nanobody C5 inhibitor"
complement C5 inhibitor medical
"Klygefa (gefurulimab), a complement C5 inhibitor"
Myasthenia Gravis Activities of Daily Living (MG-ADL) medical
"Myasthenia Gravis Activities of Daily Living (MG-ADL) total score"
Myasthenia gravis activities of daily living (MG-ADL) is an eight-item patient-reported measure that tracks how muscle weakness from myasthenia gravis affects everyday tasks such as speaking, chewing, swallowing, breathing and walking. Investors care because changes in MG-ADL are used in clinical trials and regulatory reviews to show whether a treatment delivers real, practical benefits to patients, influencing approval chances, physician adoption and market value — like a user satisfaction score for a therapy’s everyday usefulness.
open-label extension medical
"continue into an open-label extension period"
An open-label extension is a continuation of a clinical trial where all participants and researchers know which treatment is being given, often after an initial blinded phase. It allows further study of a drug's long-term safety and effectiveness. For investors, it can indicate ongoing interest and confidence in a product's potential, influencing perceptions of its future value.
terminal complement cascade medical
"C5 protein in the terminal complement cascade"
AChR antibody-positive medical
"adults with gMG who are anti-acetylcholine receptor (AChR) antibody positive"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AZN announce about Klygefa in the EU?

The European Commission approved Klygefa as an add-on to standard therapy for adults with AChR antibody-positive gMG on November 16, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
FORM 6-K
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
For the month of November 2026 
 
Commission File Number: 001-11960
 
AstraZeneca PLC
 
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X Form 40-F __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes __ No X
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 

AstraZeneca PLC
 
INDEX TO EXHIBITS
 
 
1.
Klygefa (gefurulimab) approved in the EU
 
  
16 November 2026
 
Klygefa (gefurulimab) approved in the EU for the treatment of adults with generalised myasthenia gravis (gMG)
 
Approval based on PREVAIL Phase III trial demonstrating statistically significant and clinically meaningful improvement in Myasthenia Gravis Activities of Daily Living score
 
First and only approved dual-binding nanobody C5 inhibitor in the EU, offering once-weekly subcutaneous self-administration via autoinjector with rapid and sustained disease control
 
Alexion, AstraZeneca Rare Disease’s Klygefa (gefurulimab) has been approved in the European Union (EU) as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive. Klygefa is the first and only dual-binding nanobody C5 inhibitor, offering once-weekly subcutaneous self-administration via autoinjector.
 
The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and was based on positive results from the pivotal PREVAIL Phase III trial. Results from the trial showed that Klygefa met its primary endpoint, demonstrating improvement from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 26 compared to placebo (treatment difference: -1.6 [95% CI: -2.4, -0.8], p<0.0001). A clinically meaningful improvement was observed as early as week one, and was sustained through week 26.1
 
gMG is a rare autoimmune disorder characterised by reduced muscle function and severe muscle weakness.2 An estimated 82,500 people are diagnosed with gMG in Europe 5 countries (Germany, France, UK, Italy and Spain) with approximately 66,000 being AChR-positive.3
 
Tobias Ruck, MD, Director Department of Neurology, BG University Hospital Bergmannsheil Bochum, Ruhr-University Bochum and investigator in the trial, said: “Clinical management of gMG is complex; patient symptoms, severity and trajectory can vary widely, and early, sustained disease control is critical for improving patient-related outcomes. The PREVAIL Phase III trial demonstrated the ability of gefurulimab to deliver rapid and durable disease control starting as early as week one and lasting through one year, with the added autonomy of once-weekly subcutaneous self-administration. This approval provides an important new option for physicians and patients in the EU, offering an effective and convenient approach to managing this severe, life-long rare disease.”
 
Lutgarde Allard, President, European Myasthenia Gravis Association (EuMGFA), said: “gMG is a disease marked by unique presentation, uncertainty, disruption and invisibility. For people across Europe living with this rare condition, the approval of this new medicine means more choice, convenience and the potential to regain independence in daily life. This news signifies more than scientific progress; it gives us hope and demonstrates that our community’s needs are being heard.”
 
Marc Dunoyer, Chief Executive Officer, Alexion, said: “The approval of Klygefa in Europe marks an important milestone for the gMG community, introducing a first-of-its-kind treatment that combines the proven efficacy and safety of C5 inhibition with the flexibility of once-weekly, self-administered subcutaneous dosing. This novel dual-binding nanobody is a testament to Alexion's pioneering legacy in complement science and commitment to developing differentiated therapies for people living with rare diseases.”
 
Klygefa was generally well-tolerated, and the safety profile was consistent with previous trials of C5 inhibitors eculizumab and ravulizumab in gMG.1
 
The data from the PREVAIL trial were presented at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session during the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2025 Annual Meeting and published in JAMA Neurology.1
 
Klygefa is approved in the US, Japan and other countries for certain adults with gMG. Regulatory submissions based on the PREVAIL results are under review in China and additional countries.
 
Notes
 
Generalised Myasthenia Gravis (gMG)
Generalised myasthenia gravis (gMG) is a rare autoimmune disorder characterised by reduced muscle function and severe muscle weakness.2
 
Eighty-five percent of people with gMG are AChR antibody-positive meaning they produce specific antibodies (anti-AChR) that bind to signal receptors at the neuromuscular junction (NMJ), the connection point between nerve cells and the muscles they control.4 This binding activates the complement system, causing the immune system to attack the NMJ, leading to inflammation and a breakdown in communication between the brain and the muscles.5
 
gMG can occur at any age, but it most commonly begins for women before the age of 40 and for men after the age of 60.6 Initial symptoms may include slurred speech, double vision, droopy eyelids and lack of balance; these can often lead to more severe symptoms as the disease progresses, such as impaired swallowing, choking, extreme fatigue and respiratory failure.7,8
 
PREVAIL (ALXN1720-MG-301)
PREVAIL (ALXN1720-MG-301) is a global, Phase III, randomised, double-blind, placebo-controlled, parallel, multicentre study evaluating the safety and efficacy of Klygefa (gefurulimab) in adults with generalised myasthenia gravis (gMG). The trial enrolled 260 patients from 20 countries across North America, Europe, Asia and the Pacific region. Participants were required to have a confirmed myasthenia gravis diagnosis at least three months prior to the screening visit with a positive serological test for autoantibodies against AChR and Myasthenia Gravis Foundation of America Clinical Classification Class II to IV at screening.9
 
Patients were randomised 1:1 to receive Klygefa or placebo for a total of 26 weeks in the randomised controlled treatment period. Patients received a single weight-based loading dose on Day 1, followed by regular weight-based maintenance dosing beginning on Day 8 and once every week thereafter. The primary endpoint of the change from baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score, a patient-reported scale that assesses patients’ abilities to perform daily activities, was assessed at week 26 along with multiple secondary endpoints evaluating improvement in disease-related measures.9
 
Patients who completed the randomised controlled treatment period were eligible to continue into an open-label extension period evaluating the safety and efficacy of Klygefa, which is ongoing.9
 
Klygefa (gefurulimab)
Klygefa (gefurulimab), a complement C5 inhibitor, is a novel dual-binding nanobody optimised for subcutaneous self-administration for the treatment of AChR-Ab+ gMG. The medication works by binding to the C5 protein in the terminal complement cascade, a part of the body’s immune system. When activated in an uncontrolled manner, the complement cascade over-responds, leading the body to attack its own healthy cells. Klygefa’s concurrent binding to serum albumin provides an extended half-life, enabling once-weekly dosing. 
 
Klygefa is approved in the US, Japan and other countries for certain adults with gMG. Regulatory submissions based on the PREVAIL results are under review in China and additional countries.
 
Alexion
Alexion, AstraZeneca Rare Disease, is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and delivery of life-changing medicines. A pioneering leader in rare disease for more than three decades, Alexion was the first to translate the complex biology of the complement system into transformative medicines, and today it continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities. As part of AstraZeneca, Alexion is continually expanding its global geographic footprint to serve more rare disease patients around the world. It is headquartered in Boston, US.
 
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.
 
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
 
References
1.
Gwathmey KG, Saccà F, Howard JF Jr, et al. Efficacy and safety of gefurulimab in generalized myasthenia gravis: the PREVAIL phase 3 randomized clinical trial. JAMA Neurol. 2026 Jul 27.
2.
Jung-Plath W, et al. Assessment of myasthenia gravis patients’ quality of life. The Journal of Neurosurgical Nursing. 2023;12(2):74-83.
3.
AstraZeneca Data on File - Epidemiology estimates are composed of a triangulation of different data sources including Data Monitor, Decision Resources Group, Kantar Health, and internal input. Available here. Accessed November 2026.
4.
Lazaridis K, et al. Myasthenia gravis: autoantibody specificities and their role in MG management. Front Neurol. 2020;11:596981.
5.
Huang YF, et al. Visualization and characterization of complement activation in acetylcholine receptor antibody seropositive myasthenia gravis. Muscle Nerve. 2024.
6.
Cavanagh N, et al. Exploring the impairments and allied health professional utilization in people with myasthenia gravis: a cross-sectional study. J Clin Neurosci. 2023;114:9-16.
7.
Catalin J, et al. Clinical presentation of myasthenia gravis. Thymus. 2019.
8.
Farid ZR, et al. Factors affecting generalization of ocular myasthenia gravis. Sriwijaya Journal of Ophthalmology. 2020;3(2):48-54.
9.
ClinicalTrials.gov. Safety and efficacy of ALXN1720 in adults with generalized myasthenia gravis. NCT Identifier: NCT05556096. Available here. Accessed November 2026.
 
 
Matthew Bowden
Company Secretary
AstraZeneca PLC
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
Date: 16 November 2026
 
 
By: /s/ Matthew Bowden
 
Name: Matthew Bowden
 
Title: Company Secretary

Keep reading